Canton Strategic Holdings, Inc. reported financial results for the second quarter ended June 30, 2026, recording its first operating revenue of $1,495,859 from Super Validator operations and a new locking-as-a-service (LaaS) offering that generated approximately $1.3 million. The company completed the sale of its legacy biotechnology subsidiary Gravitas Life Sciences for an unsecured promissory note with a principal amount of $3,500,000 bearing 15% payment-in-kind interest. Net loss from continuing operations was $19,254,826, or $(0.08) per share, driven by a $23.7 million unrealized loss on digital asset holdings and stock-based compensation expenses. Cash and cash equivalents increased to $37.2 million, while total assets reached $564.6 million. The company operates in the blockchain infrastructure and financial technology sector.

Canton Strategic Holdings, Inc. announced a new 2026 Share Repurchase Program on June 11, 2026, authorized by its Board of Directors to repurchase up to $50 million of outstanding Common Stock. The program allows for open market purchases or privately-negotiated transactions. On June 12, 2026, the company entered into a Rule 10b-18 Repurchase Agreement with Virtu Americas LLC, which will act as a non-exclusive agent for open market repurchases at a commission rate of $0.02 per share. The company is a strategic holdings firm.